Syros Pharmaceuticals Inc
NASDAQ:SYRS

Watchlist Manager
Syros Pharmaceuticals Inc Logo
Syros Pharmaceuticals Inc
NASDAQ:SYRS
Watchlist
Price: 0.0002 USD Market Closed
Market Cap: $5.4k

Operating Margin

-28 892.2%
Current
Declining
by 23 889.7%
vs 3-y average of -5 002.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-28 892.2%
=
Operating Income
$-111.5m
/
Revenue
$386k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-28 892.2%
=
Operating Income
$-111.5m
/
Revenue
$386k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Syros Pharmaceuticals Inc
NASDAQ:SYRS
5.4k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 98% of companies in the United States of America
Percentile
2st
Based on 14 112 companies
2st percentile
-28 892.2%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Syros Pharmaceuticals Inc
Glance View

Market Cap
5.4k USD
Industry
Biotechnology

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2016-06-30. The firm is focused on redefending the power of small molecules to control the expression of genes. The firm is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The firm's lead product candidates include Tamibarotene, SY-2101 and SY-5609. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being development for patients with select solid tumors and blood cancers.

SYRS Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-28 892.2%
=
Operating Income
$-111.5m
/
Revenue
$386k
What is Syros Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Syros Pharmaceuticals Inc is -28 892.2%, which is below its 3-year median of -5 002.5%.

How has Operating Margin changed over time?

Over the last 3 years, Syros Pharmaceuticals Inc’s Operating Margin has decreased from -482.5% to -28 892.2%. During this period, it reached a low of -28 892.2% on Sep 30, 2024 and a high of -423.2% on Dec 31, 2021.

Back to Top